Ozagrel Hydrochloride Hydrate

C₁₃H₁₂N₂O₂ · HCl · xH₂O

264.71 (anhydrous basis)

MFCD00911569

24897942

NA.77

Ozagrel hydrochloride hydrate has been used as a thromboxane synthase inhibitor:

• in high cholesterol-diet rats (HC) to test its effect on arteriolar constriction
• to pre-treat mice to test its effect on lipopolysaccharide (LPS)-induced behavioral changes
• to test its effect on arteriolar vasoconstriction in hyperglycemic mice

Ozagrel is useful in treating lacunar and thrombotic stroke. It blocks vasoconstriction and platelet aggregation. Ozagrel aids in improving the prostacyclin (PGI2)/ thromboxane A2 (TXA2) in the acute phase of cerebral ischemia. It improves endothelial dysfunction in L-methionine-induced hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID).
Ozagrel is a selective thromboxane A₂ synthase (TXA₂) inhibitor.

100

≥98% (HPLC)

solid

white to off-white

H₂O: soluble

room temp

O.Cl.OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1

1S/C13H12N2O2.ClH.H2O/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;;/h1-8,10H,9H2,(H,16,17);1H;1H2/b6-5+;;

OWIZTYOMGVTSDP-TXOOBNKBSA-N

5, 25 mg in glass bottle

13 - Non Combustible Solids

WGK 2

Eyeshields, Gloves, type N95 (US)